SCHEMBL6239405

SCHEMBL6239405

Cc1ccc(NC(=O)c2cccc(CN3CCN(C)CC3)c2)cc1Nc1nccc(-c2cccnc2)n1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 20/20 0.86
BCR P11274 15/20 0.86
KIT P10721 10/20 0.86
ABL2 P42684 5/20 0.86
LYN P07948 4/20 0.86
PDGFRA P16234 3/20 0.86
PDGFRB P09619 2/20 0.86
SRC P12931 2/20 0.86
SYK P43405 2/20 0.86
PLK4 O00444 1/20 0.86
DDX3X O00571 1/20 0.86
GAK O14976 1/20 0.86
SLC22A2 O15244 1/20 0.86
MAPK13 O15264 1/20 0.86
CA12 O43570 1/20 0.86
SLC22A3 O75751 1/20 0.86
ABCB11 O95342 1/20 0.86
EGFR P00533 1/20 0.86
CA1 P00915 1/20 0.86
CA2 P00918 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667846 0.94 ABL1 (0.83) ABL1BCRKITABL2LYN
Imatinib SCHEMBL2236091 0.92 ABL1 (1.00) ABL1BCRKITABL2LYN
Imatinib SCHEMBL3827 0.92 ABL1 (1.00) ABL1BCRKITABL2LYN
Imatinib SCHEMBL29351601 0.92 ABL1 (1.00) ABL1BCRKITABL2LYN
Imatinib SCHEMBL29355523 0.92 ABL1 (1.00) ABL1BCRKITABL2LYN
Imatinib SCHEMBL1977949 0.92 ABL1 (0.98) ABL1BCRKITABL2LYN
Imatinib SCHEMBL15201213 0.92 ABL1 (0.98) ABL1BCRKITABL2LYN
Imatinib SCHEMBL16431247 0.92 ABL1 (0.98) ABL1BCRKITABL2LYN
Imatinib SCHEMBL3138052 0.92 ABL1 (0.98) ABL1BCRKITABL2LYN
Imatinib SCHEMBL2929858 0.92 ABL1 (0.98) ABL1BCRKITABL2LYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111329863-A Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia 黄泳华 2020-06-26 CN claimed
CN-111298127-A Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same 黄泳华 2020-06-19 CN claimed
CN-110559443-A composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same 黄泳华 2019-12-13 CN claimed
CN-110559299-A composition containing pyridyl pyrimidinamine compound and application thereof 黄泳华 2019-12-13 CN claimed
CN-111329863-A Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia 黄泳华 2020-06-26 CN disclosed
CN-111298127-A Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same 黄泳华 2020-06-19 CN disclosed
CN-110559443-A composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same 黄泳华 2019-12-13 CN disclosed
CN-110559299-A composition containing pyridyl pyrimidinamine compound and application thereof 黄泳华 2019-12-13 CN disclosed
EP-1553948-A1 COMBINATION OF A) N-(5(5-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO)-2-METHYLPHENYL)-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND B) A HISTONE DEACETYLASE INHIBITOR FOR THE TREATMENT OF LEUKEMIA VIRGINIA COMMONWEALTH UNIVERSITY (US) 2005-07-20 EP disclosed